Kimberly-Clark (NASDAQ:KMB) & Niagen Bioscience (NASDAQ:NAGE) Financial Comparison

Kimberly-Clark (NASDAQ:KMB) and Niagen Bioscience (NASDAQ:NAGE) are both consumer staples companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Profitability

This table compares Kimberly-Clark and Niagen Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kimberly-Clark	11.79%	143.92%	14.21%
Niagen Bioscience	12.39%	17.95%	13.17%

Risk & Volatility

Kimberly-Clark has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500.

Institutional and Insider Ownership

76.3% of Kimberly-Clark shares are owned by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are owned by institutional investors. 0.7% of Kimberly-Clark shares are owned by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Kimberly-Clark and Niagen Bioscience”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kimberly-Clark	$16.45 billion	2.22	$2.02 billion	$5.88	18.64
Niagen Bioscience	$129.42 million	1.50	$17.38 million	$0.18	13.53

Kimberly-Clark has higher revenue and earnings than Niagen Bioscience. Niagen Bioscience is trading at a lower price-to-earnings ratio than Kimberly-Clark, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Kimberly-Clark and Niagen Bioscience, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kimberly-Clark	2	11	4	1	2.22
Niagen Bioscience	0	1	3	1	3.00

Kimberly-Clark presently has a consensus target price of $115.73, indicating a potential upside of 5.58%. Niagen Bioscience has a consensus target price of $10.33, indicating a potential upside of 324.37%. Given Niagen Bioscience’s stronger consensus rating and higher probable upside, analysts clearly believe Niagen Bioscience is more favorable than Kimberly-Clark.

Summary

Kimberly-Clark beats Niagen Bioscience on 9 of the 14 factors compared between the two stocks.

About Kimberly-Clark

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products in the United States. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The company’s Personal Care segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Thinx, Poise, Depend, Plenitud, Softex, and other brand names. Its Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The company’s K-C Professional segment offers wipers, tissues, towels, apparel, personal protective equipment, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. It also sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to distributors, manufacturing, lodging, office building, food service, and public facilities, as well as through e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

About Niagen Bioscience

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.